Discovery of a novel 2,4‐thiazolidinedione derivative as dual inhibitor of β‐catenin/TCF4 interaction and tubulin polymerization in colon cancer cells
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.202400796 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Yating Guo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: beta Catenin, Colonic Neoplasms, Antineoplastic Agents, Tubulin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Innovation Fund for Postgraduate Students of Central South University.
Abstract (Originalsprache)
Hyperactivation of the Wnt/β‐catenin signaling pathway has been widely recognized as a pathogenic mechanism for colorectal cancer (CRC). Based on a previously reported lead compound, iCRT14, a series of 2,4‐thiazolidinedione derivatives were designed, synthesized, and evaluated in vitro for their antiproliferative activity against colon cancer cells. Compound 15k exhibited the most potent activity against the HCT116 and SW480 cell lines. Compound 15k inhibited Wnt/β‐catenin signaling by disrupting the protein–protein interactions between β‐catenin and TCF4. Compound 15k simultaneously inhibited tubulin polymerization, disorganized the microtubule network, and arrested the cell cycle at the G2/M phase, offering an additional mechanism of action and 15k induced cell apoptosis by activating caspase‐3 and poly(ADP‐ribose) polymerase. Additionally, compound 15k inhibited cell migration without affecting the levels of β‐catenin protein. These results offer guidance for developing the current series as potential new anticancer therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China.
- Hunan Key Laboratory of Small Molecules for Diagnosis and Treatment of Chronic Disease, Changsha, Hunan, China.
- Hunan Key Laboratory of Organ Fibrosis, Changsha, Hunan, China.
Förderung
- Innovation Fund for Postgraduate Students of Central South University
Zitieren
APA
Guo, Y., Cao, M., Li, Z., Zhou, H., Chen, Z., & Li, Q. (2025). Discovery of a novel 2,4‐thiazolidinedione derivative as dual inhibitor of β‐catenin/TCF4 interaction and tubulin polymerization in colon cancer cells. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400796
Vancouver
Guo Y, Cao M, Li Z, Zhou H, Chen Z, Li Q. Discovery of a novel 2,4‐thiazolidinedione derivative as dual inhibitor of β‐catenin/TCF4 interaction and tubulin polymerization in colon cancer cells. Archiv der Pharmazie. 2025. doi:10.1002/ardp.202400796
BibTeX
@article{Guo2025,
author = {Guo, Yating and Cao, Meng and Li, Zhaohui and Zhou, Hongfei and Chen, Zhuo and Li, Qianbin},
title = {Discovery of a novel 2,4‐thiazolidinedione derivative as dual inhibitor of β‐catenin/TCF4 interaction and tubulin polymerization in colon cancer cells},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.202400796}
}
EUVIMED